中国现代医生
中國現代醫生
중국현대의생
CHINA MODERN DOCTOR
2014年
26期
34-37
,共4页
1型糖尿病%自体造血干细胞移植%动态血糖监测%胰岛素
1型糖尿病%自體造血榦細胞移植%動態血糖鑑測%胰島素
1형당뇨병%자체조혈간세포이식%동태혈당감측%이도소
Type 1 diabetes%Autologous hematopoietic stem cell transplantation%Glucose monitoring%Insulin
目的：对比自体造血干细胞移植和胰岛素对1型糖尿病患者血糖控制作用。方法将40例初发1型糖尿病患者根据治疗方法分为移植组15例和胰岛素组25例，移植组采用自体造血干细胞移植治疗，胰岛素组采用常规胰岛素注射治疗，随访>12个月，治疗12个月后采用动态血糖监测评价血糖控制情况。结果移植组治疗后MBG、LAGE均显著低于治疗前(P<0.05)，治疗后移植组MBG、SDBG、LAGE、MAGE均显著低于胰岛素组(P<0.05)。移植组治疗后HbA1c较治疗前显著降低并显著低于胰岛素组(P<0.05)，移植组2例分别在9.3、11.2个月时停用胰岛素，胰岛素平均减量(53.28±21.29)%，移植组治疗后胰岛素用量显著降低并显著低于胰岛素组(P<0.05)，移植组治疗后血糖<3.9 mmol/L时间百分比，血糖>11.1 mmol/L时间百分比均较治疗前显著降低，并显著低于胰岛素组，血糖(3.9~11.1)mmol/L时间百分比较治疗前显著增加，并显著高于胰岛素组(P<0.05)。所有患者未出现严重不良反应。结论相比传统胰岛素注射治疗，自体造血干细胞移植能有效控制1型糖尿病患者血糖，可降低血糖波动，减少胰岛素依赖。
目的：對比自體造血榦細胞移植和胰島素對1型糖尿病患者血糖控製作用。方法將40例初髮1型糖尿病患者根據治療方法分為移植組15例和胰島素組25例，移植組採用自體造血榦細胞移植治療，胰島素組採用常規胰島素註射治療，隨訪>12箇月，治療12箇月後採用動態血糖鑑測評價血糖控製情況。結果移植組治療後MBG、LAGE均顯著低于治療前(P<0.05)，治療後移植組MBG、SDBG、LAGE、MAGE均顯著低于胰島素組(P<0.05)。移植組治療後HbA1c較治療前顯著降低併顯著低于胰島素組(P<0.05)，移植組2例分彆在9.3、11.2箇月時停用胰島素，胰島素平均減量(53.28±21.29)%，移植組治療後胰島素用量顯著降低併顯著低于胰島素組(P<0.05)，移植組治療後血糖<3.9 mmol/L時間百分比，血糖>11.1 mmol/L時間百分比均較治療前顯著降低，併顯著低于胰島素組，血糖(3.9~11.1)mmol/L時間百分比較治療前顯著增加，併顯著高于胰島素組(P<0.05)。所有患者未齣現嚴重不良反應。結論相比傳統胰島素註射治療，自體造血榦細胞移植能有效控製1型糖尿病患者血糖，可降低血糖波動，減少胰島素依賴。
목적：대비자체조혈간세포이식화이도소대1형당뇨병환자혈당공제작용。방법장40례초발1형당뇨병환자근거치료방법분위이식조15례화이도소조25례，이식조채용자체조혈간세포이식치료，이도소조채용상규이도소주사치료，수방>12개월，치료12개월후채용동태혈당감측평개혈당공제정황。결과이식조치료후MBG、LAGE균현저저우치료전(P<0.05)，치료후이식조MBG、SDBG、LAGE、MAGE균현저저우이도소조(P<0.05)。이식조치료후HbA1c교치료전현저강저병현저저우이도소조(P<0.05)，이식조2례분별재9.3、11.2개월시정용이도소，이도소평균감량(53.28±21.29)%，이식조치료후이도소용량현저강저병현저저우이도소조(P<0.05)，이식조치료후혈당<3.9 mmol/L시간백분비，혈당>11.1 mmol/L시간백분비균교치료전현저강저，병현저저우이도소조，혈당(3.9~11.1)mmol/L시간백분비교치료전현저증가，병현저고우이도소조(P<0.05)。소유환자미출현엄중불량반응。결론상비전통이도소주사치료，자체조혈간세포이식능유효공제1형당뇨병환자혈당，가강저혈당파동，감소이도소의뢰。
Objective To compare autologous stem cell transplantation and insulin action glycemic control in patients with type 1 diabetes. Methods A total of 40 patients with newly diagnosed type 1 diabetes patients were divided into transplantation group of 15 patients and 25 cases of insulin groups accorded to treatment, transplantation group treated with autologous hematopoietic stem cell transplantation, insulin group with conventional insulin injection therapy, fol-low-up of > 12 months, 12 months after treatment the adoption of continuous glucose monitoring and evaluation of glycemic control was evaluated. Results Transplantation group after treatment, MBG, LAGE were significantly lower than before treatment (P<0.05), after treatment, transplantation group MBG, SDBG, LAGE, MAGE were significantly lower than insulin group (P<0.05). After the transplant group therapy significantly reduced HbA1c compared with be-fore treatment and significantly lower than in the insulin group(P<0.05), group 2 patients transplanted insulin were de-activated in 9.3,11.2 months, an average reduction of insulin (53.28±21.29)%, after treatment, the amount of insulin significantly reduced transplant group and significantly lower than the insulin group (P<0.05), post-transplant group therapy blood glucose <3.9 mmol/L percentage of time, blood glucose > 11.1 mmol/L percentage of time were signifi-cantly lower than before treatment, and significantly lower than insulin, glucose (3.9~11.1) mmol/L percentage of time increase in the percentage of time now compared to before treatment, and significantly higher than that in the insulin group (P<0.05). All patients with severe adverse reactions occur. Conclusion Compared to conventional insulin injec-tion therapy, autologous hematopoietic stem cell transplantation can effectively control blood sugar with type 1 diabetes, can reduce blood sugar fluctuations, reduce insulin dependence.
